RAB22A overexpression promotes the tumor growth of melanoma.
Malignant melanoma is the most aggressive type of skin cancer. RAB22A, a member of RAS oncogene family, has been found to be significantly upregulated in multiple human cancers. In the present study, we found that RAB22A mRNA expression was significantly upregulated in melanoma tissues (including 60 primary melanomas and 84 metastatic melanomas) compared to benign nevi (n = 20), which were significantly higher in metastatic melanoma tissues than primary tissues. Immunohistochemistry data further showed that the positive immunoreactivity of RAB22A was detected in 66% (95/144) melanoma tissues, but not in benign nevi. Moreover, high expression of RAB22A was significantly associated with advanced clinical stage in melanoma. Furthermore, patients with high RAB22A expression had shorter overall survival compared those with low expression of RAB22A. In-vitro study showed that RAB22A was also upregulated in melanoma cell lines WM35, A375, WM451, and SK-MEL-1, when compared with the normal melanocyte HM cells. Knockdown of RAB22A significantly reduced the proliferation, migration and invasion of melanoma A375 cells, while overexpression of RAB22A significantly promoted these malignant phenotypes. In addition, RAB22A was found to be a target of miR-203, a tumor suppressive miRNA in melanoma. Besides, miR-203 was downregulated in melanoma tissues and cell lines, when compared with benign nevi and HM cells, respectively. Taken these findings together, our study could validate an oncogenic role of RAB22A in melanoma, suggesting that RAB22A may be a potential therapeutic target for melanoma.
Department of Emergency, Xiangya Hospital, Central South University, Changsha, China.
Feng
F
Su
Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yifei
Y
Chen
Department of Neurology, The Second Affiliated Hospital of Hunan University of TCM, Changsha, Hunan, China.
Shilin
S
Zhu
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.|Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Fangfang
F
Li
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.|Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Shuang
S
Zhao
Institute of Medical Science Research, Xiangya Hospital, Central South University, Hunan, China.
Lisa
L
Wu
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.|Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xiang
X
Chen
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.|Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Juan
J
Su
D000328:Adult; D000368:Aged; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000737:chemistry / Q000401:mortality / Q000473:pathology*; D035683:MicroRNAs / Q000502:physiology; D008875:Middle Aged; D011379:Prognosis; D020691:rab GTP-Binding Proteins / Q000032:analysis / Q000235:genetics / Q000502:physiology*
C546703:MIRN203 microRNA, human; D035683:MicroRNAs; C484191:RAB22A protein, human; D020691:rab GTP-Binding Proteins
RAB22A; malignant phenotype; melanoma; microRNA; prognosis
J Cell Sci. 2002 Mar 1;115(Pt 5):899-911
11870209
Clin Cancer Res. 2014 Dec 1;20(23 ):6187-99
25294901
Med Res Rev. 2017 Jan;37(1):98-148
27569556
Proc Natl Acad Sci U S A. 2014 Aug 5;111(31):E3234-42
24938788
J Biol Chem. 2012 Apr 6;287(15):11769-77
22354972
Stem Cells. 2016 Aug;34(8):1997-2007
27251010
Oncol Rep. 2016 May;35(5):3000-8
26883716
Environ Toxicol. 2015 Sep 29;:null
26420756
Cancer Biomark. 2015;15(5):599-608
26406949
J Cell Sci. 2001 Nov;114(Pt 22):4041-9
11739636
Expert Rev Anticancer Ther. 2015 Jan;15(1):101-8
25248282
Neoplasia. 2005 Apr;7(4):303-11
15967107
Gene Expr. 2002;10(5-6):231-42
12450215
Cell. 2004 Jan 23;116(2):281-97
14744438
PLoS One. 2015 Sep 18;10 (9):e0132225
26382657
Eur J Med Res. 2008 Nov 24;13(11):500-4
19073385
Virchows Arch. 2012 Oct;461(4):441-8
22956368
Sci Rep. 2016 Apr 05;6:23892
27046651
Ophthalmology. 2011 Sep;118(9):1881-5
21704381
Biochem Biophys Res Commun. 2016 Aug 5;476(4):400-5
27237979
Int J Clin Exp Pathol. 2015 Oct 01;8(10 ):13249-54
26722525
Cell. 2005 Jul 15;122(1):6-7
16009126
Exp Ther Med. 2014 Jul;8(1):309-315
24944639
Exp Cell Res. 2005 Apr 1;304(2):339-53
15748882
Med Oncol. 2015 Jan;32(1):331
25429829
Biochem Biophys Res Commun. 2015 Jan 2;456(1):361-6
25475727